Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2024Pediatric Blood & Cancer

BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChan‐Juan WangMinistry of Education of the People's Republic of ChinaTZTing ZhuNational Clinical Research Center for Digestive DiseasesCZChen‐Zi ZhaoFujian University of Traditional Chinese Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e65d10b6db6435875eb539https://doi.org/10.1002/pbc.31099
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BRAF V600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis2021 · 13 citations
  2. 2Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis2022 · 21 citations
  3. 3A circulating subset of BRAFV600E‐positive cells in infants with high‐risk Langerhans cell histiocytosis treated with BRAF inhibitors2021 · 9 citations
  4. 4Circulating tumor cells: biology and clinical significance2021 · 1,012 citations
  5. 5Recurrent BRAF mutations in Langerhans cell histiocytosis2010 · 1,259 citations